Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice.
Connexin32 (Cx32) is the major gap junction forming protein in liver. We have recently shown that hepatocarcinogenesis is strongly enhanced in mice deficient in Cx32, demonstrating that lack of functional Cx32 accelerates liver tumorigenesis. Many tumor-promoting agents, including phenobarbital, block gap junctional intercellular communication in vitro, and it has been suggested that this effect is relevant for clonal expansion of neoplastic cells in vivo. We have now tested this hypothesis by analyzing the potency of phenobarbital as a liver tumor promoter in male Cx32-wild-type (Cx32(Y/+)) and Cx32-null (Cx32(Y/-)) mice. Preneoplastic and neoplastic liver lesions were induced in 6-week-old male mice by a single injection of 90 microg/g body weight of N-nitrosodiethylamine, and groups of mice were subsequently kept on phenobarbital-containing (0.05%) or control diet for 39 weeks. Frozen liver sections were prepared, and (pre)neoplastic lesions were identified by their deficiency in glucose-6-phosphatase staining. In addition, the number and size of macroscopically visible tumors were monitored. Phenobarbital led to a approximately 5-fold increase in the volume fraction occupied by glucose-6-phosphatase-deficient liver lesions in Cx32(Y/+) mice, whereas there was no such increase in Cx32(Y/-) mice. Even more pronounced differences were observed with respect to tumor response. Whereas phenobarbital clearly promoted the occurrence of numerous large hepatomas in Cx32(Y/+) mice, no such effect was seen in Cx32(Y/-) mice. These results demonstrate, for the first time, that functional Cx32 protein is required for tumor promotion by phenobarbital.
Moennikes
O
O
Institut für Toxikologie, Tübingen, Germany.
Buchmann
A
A
Romualdi
A
A
Ott
T
T
Werringloer
J
J
Willecke
K
K
Schwarz
M
M
D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D003043:Cocarcinogenesis; D017630:Connexins / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D003433:Crosses, Genetic; D004052:Diethylnitrosamine / Q000633:toxicity; D004357:Drug Synergism; D005260:Female; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects / Q000201:enzymology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000209:etiology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009929:Organ Size / Q000187:drug effects; D010634:Phenobarbital / Q000633:toxicity*; D011230:Precancerous Conditions / Q000139:chemically induced / Q000209:etiology; D000097002:Gap Junction beta-1 Protein
D002273:Carcinogens; D017630:Connexins; D004052:Diethylnitrosamine; D010634:Phenobarbital; D000097002:Gap Junction beta-1 Protein